By: Janek S.B. No. 943
 
 
A BILL TO BE ENTITLED
AN ACT
relating to the licensing and regulation of wholesale distributors
of prescription drugs; providing penalties.
       BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
       SECTION 1.  Section 431.401, Health and Safety Code, is
amended by amending Subdivisions (3), (5), and (11) and adding
Subdivisions (3-a), (3-b), (4-a), (4-b), (10-a), and (12) to read
as follows:
             (3)  "Pharmacy [Chain pharmacy] warehouse" means a
location for which a person holds a wholesale drug distribution
license under this subchapter, that serves [primarily] as a central
warehouse for drugs or devices, and from which intracompany sales
or transfers of drugs or devices are made to a group of pharmacies
under common ownership and control.
             (3-a)  "Co-licensed product partner" means one of two
or more parties that have the right to engage in the manufacturing
or marketing of a prescription drug consistent with the United
States Food and Drug Administration's regulations and guidances
implementing the Prescription Drug Marketing Act of 1987 (Pub. L.
No. 100-293).
             (3-b)  "Drop shipment" means the sale of a prescription
drug to a wholesale distributor by the manufacturer of the
prescription drug, or by the manufacturer's co-licensed product
partner, third-party logistics provider, or exclusive distributor,
in which:
                   (A)  the wholesale distributor takes title but not
physical possession of the prescription drug;
                   (B)  the wholesale distributor invoices the
pharmacy, pharmacy warehouse, or other person authorized by law to
dispense or administer the drug to a patient; and
                   (C)  the pharmacy, pharmacy warehouse, or other
authorized person receives delivery of the prescription drug
directly from the manufacturer or the manufacturer's third-party
logistics provider or exclusive distributor.
             (4-a)  "Manufacturer" means a person licensed or
approved by the United States Food and Drug Administration to
engage in the manufacture of drugs or devices, consistent with the
federal agency's definition of "manufacturer" under the agency's
regulations and guidances implementing the Prescription Drug
Marketing Act of 1987 (Pub. L. No. 100-293).  The term does not
include a pharmacist engaged in compounding that is done within the
practice of pharmacy and pursuant to a prescription drug order or
initiative from a practitioner for a patient or prepackaging that
is done in accordance with Section 562.154, Occupations Code.
             (4-b)  "Manufacturer's exclusive distributor" means a
person who holds a wholesale distributor license under this
subchapter, who contracts with a manufacturer to provide or
coordinate warehousing, distribution, or other services on behalf
of the manufacturer, and who takes title to, but does not have
general responsibility to direct the sale or disposition of, the
manufacturer's prescription drug. A manufacturer's exclusive
distributor must be an authorized distributor of record to be
considered part of the normal distribution channel.
             (5)  "Normal distribution channel [chain]" means a
chain of custody for a prescription drug, either directly or by drop
shipment, from the manufacturer of the prescription drug, the
manufacturer to the manufacturer's co-licensed product partner,
the manufacturer to the manufacturer's third-party logistics
provider, or the manufacturer to the manufacturer's exclusive
distributor, to:
                   (A)  [a manufacturer to an authorized distributor
of record or to a wholesale distributor licensed under this
subchapter to] a pharmacy [or practitioner] to:
                         (i)  a patient; or
                         (ii)  another designated person authorized
by law to dispense or administer the drug to a patient;
                   (B)  an authorized distributor of record to:
                         (i)  a pharmacy to a patient; or
                         (ii)  another designated person authorized
by law to dispense or administer the drug to a patient;
                   (C)  [a manufacturer to] an authorized
distributor of record to a pharmacy warehouse to the pharmacy
warehouse's intracompany pharmacy or another designated person
authorized by law to dispense or administer the drug [one other
authorized distributor of record to a pharmacy or practitioner] to
a patient; [or]
                   (D) [(C)  a manufacturer to an authorized
distributor of record to] a [chain] pharmacy warehouse to the
pharmacy warehouse's intracompany pharmacy or another designated
person authorized by law to dispense or administer the drug [a
pharmacy or practitioner] to a patient; or
                   (E)  a person authorized by law to prescribe a
prescription drug that by law may be administered only under the
supervision of the prescriber.
             (10-a)  "Third-party logistics provider" means a
person who holds a wholesale distributor license under this
subchapter, who contracts with a prescription drug manufacturer to
provide or coordinate warehousing, distribution, or other services
on behalf of the manufacturer, and who does not take title to the
prescription drug or have general responsibility to direct the
prescription drug's sale or disposition. A third-party logistics
provider must be an authorized distributor of record to be
considered part of the normal distribution channel.
             (11)  "Wholesale distribution" means distribution of
prescription drugs to a person other than a consumer or patient[,
and includes distribution by a manufacturer, repackager, own label
distributor, broker, jobber, warehouse, retail pharmacy that
conducts wholesale distribution, or wholesaler]. The term does not
include:
                   (A)  intracompany sales of prescription drugs,
which means transactions or transfers of prescription drugs between
a division, subsidiary, parent, or affiliated or related company
that is under common ownership and control, or any transaction or
transfer between co-license holders of a co-licensed product [of a
corporate entity];
                   (B)  the sale, purchase, distribution, trade, or
transfer of prescription drugs or the offer to sell, purchase,
distribute, trade, or transfer a prescription drug for emergency
medical reasons;
                   (C)  the distribution of prescription drug
samples by a representative of a manufacturer;
                   (D)  the return of drugs by a hospital, health
care entity, [retail pharmacy, chain pharmacy warehouse,] or
charitable institution in accordance with 21 C.F.R. Section 203.23;
[or]
                   (E)  the sale of reasonable quantities [delivery]
by a retail pharmacy of a prescription drug to [a patient or a
patient's agent under the lawful order of] a licensed practitioner
for office use;
                   (F)  the sale, purchase, or trade of a drug, an
offer to sell, purchase, or trade a drug, or the dispensing of a
drug under a prescription;
                   (G)  the sale, transfer, merger, or consolidation
of all or part of the business of a pharmacy from or with another
pharmacy, whether accomplished as a purchase and sale of stock or
business assets;
                   (H)  the sale, purchase, distribution, trade, or
transfer of a prescription drug from one authorized distributor of
record to one additional authorized distributor of record if:
                         (i)  the manufacturer states in writing to
the receiving distributor that the manufacturer is unable to supply
the prescription drug; and
                         (ii)  the supplying distributor states in
writing that the prescription drug being supplied had until that
time been exclusively in the normal distribution channel;
                   (I)  the delivery of, or offer to deliver, a
prescription drug by a common carrier solely in the common
carrier's usual course of business of transporting prescription
drugs, if the common carrier does not store, warehouse, or take
legal ownership of the prescription drug; or
                   (J)  the sale or transfer from a retail pharmacy
or pharmacy warehouse of expired, damaged, returned, or recalled
prescription drugs to the original manufacturer or to a third-party
returns processor.
             (12)  "Wholesale distributor" means a person engaged in
the wholesale distribution of prescription drugs, including a
manufacturer, repackager, own-label distributor, private-label
distributor, jobber, broker, manufacturer warehouse, distributor
warehouse, or other warehouse, manufacturer's exclusive
distributor, authorized distributor of record, drug wholesaler or
distributor, independent wholesale drug trader, specialty
wholesale distributor, third-party logistics provider, retail
pharmacy that conducts wholesale distribution, and pharmacy
warehouse that conducts wholesale distribution.
       SECTION 2.  Section 431.4031, Health and Safety Code, is
amended to read as follows:
       Sec. 431.4031.  EXEMPTION FROM CERTAIN PROVISIONS FOR
CERTAIN WHOLESALE DISTRIBUTORS.  A wholesale distributor that
distributes prescription drugs that are medical gases or a
wholesale distributor that is a manufacturer or a third-party
logistics provider on behalf of a manufacturer is exempt from
Sections 431.404(a)(5) and (6), (b), [431.404(b)] and (c),
431.4045, 431.405, 431.407, and 431.408[, 431.412, and 431.413].
       SECTION 3.  Subsections (a), (b), and (d), Section 431.404,
Health and Safety Code, are amended to read as follows:
       (a)  An applicant for a license under this subchapter must
submit an application to the department on the form prescribed by
the department. The application must contain:
             (1)  the name, full business address, and telephone
number of the applicant;
             (2)  all trade or business names under which the
business is conducted;
             (3) [(2)]  the address, [and] telephone number, and
name of a contact person for each of the applicant's places of
business [of each place of business that is licensed];
             (4) [(3)]  the type of business entity and:
                   (A)  if the business is a sole proprietorship, the
name of the proprietor;
                   (B)  if the business is a partnership, the name of
the partnership and each of the partners; or
                   (C)  if the business is a corporation, the name of
the corporation, the place of incorporation, and the name and title
of each corporate officer and director [the name and residence
address of:
                   [(A)  the proprietor, if the business is a
proprietorship;
                   [(B)  all partners, if the business is a
partnership; or
                   [(C)  all principals, if the business is an
association];
             [(4)  the date and place of incorporation, if the
business is a corporation;]
             (5)  [the names and business addresses of the
individuals in an administrative capacity showing:
                   [(A)  the managing proprietor, if the business is
a proprietorship;
                   [(B)  the managing partner, if the business is a
partnership;
                   [(C)  the officers and directors, if the business
is a corporation; or
                   [(D)  the persons in a managerial capacity, if the
business is an association;
             [(6)]  the name and[,] telephone number of, and any
information necessary to complete a criminal history record check
on, a designated representative of each place of business; and
             (6) [(7)  the state of incorporation, if the business
is a corporation;
             [(8)]  a list of all licenses and permits issued to the
applicant by any other state under which the applicant is permitted
to purchase or possess prescription drugs[; and
             [(9)  the name of the manager for each place of
business].
       (b)  Each person listed in Subsection (a)(5) [Subsections
(a)(6) and (a)(9)] shall provide the following to the department:
             (1)  the person's places of residence for the past seven
years;
             (2)  the person's date and place of birth;
             (3)  the person's occupations, positions of employment,
and offices held during the past seven years;
             (4)  the business name and address of any business,
corporation, or other organization in which the person held an
office under Subdivision (3) or in which the person conducted an
occupation or held a position of employment;
             (5)  a statement of whether during the preceding seven
years the person was the subject of a proceeding to revoke a license
or a criminal proceeding and the nature and disposition of the
proceeding;
             (6)  a statement of whether during the preceding seven
years the person has been enjoined, either temporarily or
permanently, by a court from violating any federal or state law
regulating the possession, control, or distribution of
prescription drugs, including the details concerning the event;
             (7)  a written description of any involvement by the
person as an officer or director with any business, including any
investments, other than the ownership of stock in a publicly traded
company or mutual fund during the past seven years, that
manufactured, administered, prescribed, distributed, or stored
pharmaceutical products and any lawsuits in which the businesses
were named as a party;
             (8)  a description of any misdemeanor or felony offense
for which the person, as an adult, was found guilty, regardless of
whether adjudication of guilt was withheld or whether the person
pled guilty or nolo contendere;
             (9)  a description of any criminal conviction of the
person under appeal, a copy of the notice of appeal for that
criminal offense, and a copy of the final written order of an appeal
not later than the 15th day after the date of the appeal's
disposition; and
             (10)  a photograph of the person taken not earlier than
180 [30] days before the date the application was submitted.
       (d)  An applicant or license holder shall submit to [file
with] the department [a written notice of] any change in or
correction to the information required under this section in the
form and manner prescribed by the department.
       SECTION 4.  Subchapter N, Chapter 431, Health and Safety
Code, is amended by adding Section 431.4045 to read as follows:
       Sec. 431.4045.  INSPECTION REQUIRED.  The department may not
issue a wholesale distributor license to an applicant under this
subchapter unless the department:
             (1)  conducts a physical inspection of the place of
business at the address provided by the applicant under Section
431.404; and
             (2)  determines that the designated representative of
the place of business meets the qualifications required by Section
431.405.
       SECTION 5.  Section 431.405, Health and Safety Code, is
amended to read as follows:
       Sec. 431.405.  QUALIFICATIONS FOR LICENSE.  To qualify for
the issuance or renewal of a wholesale distributor license under
this subchapter, the designated representative of an applicant or
license holder must:
             (1)  be at least 21 years of age;
             (2)  have been employed full-time for at least three
years by a pharmacy or a wholesale distributor in a capacity related
to the dispensing or distributing of prescription drugs, including
recordkeeping for the dispensing or distributing of prescription
drugs;
             (3)  be employed by the applicant full-time in a
managerial-level position;
             (4)  be actively involved in and aware of the actual
daily operation of the wholesale distributor;
             (5)  be physically present at the applicant's place of
business during regular business hours, except when the absence of
the designated representative is authorized, including sick leave
and vacation leave;
             (6)  serve as a designated representative for only one
applicant at any one time, except in a circumstance in which more
than one licensed wholesale distributor is colocated in the same
place of business and the wholesale distributors are members of an
affiliated group, as defined by Section 1504, Internal Revenue Code
of 1986;
             (7)  not have been convicted of a violation of any
federal, state, or local laws relating to wholesale or retail
prescription drug distribution or the distribution of controlled
substances; and
             (8)  not have been convicted of a felony under a
federal, state, or local law.
       SECTION 6.  Section 431.408, Health and Safety Code, is
amended by adding Subsections (a-1) and (c-1) to read as follows:
       (a-1)  A pharmacy warehouse that is not engaged in wholesale
distribution is exempt from the bond requirement under Subsection
(a).
       (c-1)  A single bond is sufficient to cover all places of
business operated by a wholesale distributor in this state.
       SECTION 7.  Subchapter N, Chapter 431, Health and Safety
Code, is amended by adding Section 431.4095 to read as follows:
       Sec. 431.4095.  RENEWAL NOTIFICATION; CHANGE OR RENEWAL.  
(a)  Before the expiration of a license issued under this
subchapter, the department shall send to each licensed wholesale
distributor a form containing a copy of the information the
distributor provided to the department under Section 431.404.
       (b)  Not later than the 30th day after the date the wholesale
distributor receives the form under Subsection (a), the wholesale
distributor shall identify and state under oath to the department
any change in or correction to the information.
       SECTION 8.  Subchapter N, Chapter 431, Health and Safety
Code, is amended by adding Sections 431.4101 and 431.4102 to read as
follows:
       Sec. 431.4101.  CONTINUING TRAINING.  Designated
representatives identified in Section 431.404(a)(5) shall
successfully complete continuing training regarding applicable
federal and state laws governing the wholesale distribution of
prescription drugs as required by department rule.
       Sec. 431.4102.  CONFIDENTIALITY. Information provided
under Section 431.404 may not be disclosed to any person other than
the department for licensing or monitoring purposes.
       SECTION 9.  Section 431.411, Health and Safety Code, is
amended by amending Subsection (a) and adding Subsections (a-1),
(a-2), and (e) to read as follows:
       (a)  A wholesale distributor shall receive prescription drug
returns or exchanges from a pharmacy or [chain] pharmacy warehouse
in accordance with the terms and conditions of the agreement
between the wholesale distributor and the pharmacy or [chain]
pharmacy warehouse.  An expired, damaged, recalled, or otherwise
nonsalable prescription drug that is returned to the wholesale
distributor may be distributed by the wholesale distributor only to
either the original manufacturer or a third-party returns
processor. The returns or exchanges, salable or otherwise,
received by the wholesale distributor as provided by this
subsection, including any redistribution of returns or exchanges by
the wholesale distributor, are not subject to the pedigree
requirement under Section 431.412 if the returns or exchanges are
exempt from pedigree under:
             (1)  Section 503, Prescription Drug Marketing Act of
1987 (21 U.S.C. Section 353(c)(3)(B));
             (2)  the regulations adopted by the secretary to
administer and enforce that Act; or
             (3)  the interpretations of that Act set out in the
compliance policy guide of the United States Food and Drug
Administration.
       (a-1)  Each [In connection with the returned goods process,
a] wholesale distributor and pharmacy shall administer the process
of drug returns and exchanges to ensure that the process is secure
and does not permit [should establish appropriate business
practices and exercise due diligence designed to prevent] the entry
of adulterated or counterfeit drugs into the distribution channel.
       (a-2)  Notwithstanding any provision of state or federal law
to the contrary, a person that has not otherwise been required to
obtain a wholesale license under this subchapter and that is a
pharmacy engaging in the sale or transfer of expired, damaged,
returned, or recalled prescription drugs to the originating
wholesale distributor or manufacturer and pursuant to federal
statute, rules, and regulations, including the United States Food
and Drug Administration's applicable guidances implementing the
Prescription Drug Marketing Act of 1987 (Pub. L. No. 100-293), is
exempt from wholesale licensure requirements under this
subchapter.
       (e)  A manufacturer or wholesale distributor may not accept
payment for, or allow the use of a person's credit to establish an
account for the purchase of, prescription drugs from any person
other than the owner of record, the chief executive officer, or the
chief financial officer listed on the license of a person legally
authorized to receive prescription drugs. Any account for the
purchase of prescription drugs must be established in the name of
the license holder or the license holder's professional entity, as
that term is defined by Section 301.003, Business Organizations
Code. This subsection does not prohibit a pharmacy or pharmacy
warehouse from receiving prescription drugs where the payment for
the prescription drugs is processed through the pharmacy's or
pharmacy warehouse's contractual wholesale distributor.
       SECTION 10.  Section 431.412, Health and Safety Code, is
amended by amending Subsections (a) and (d) and adding Subsection
(b-1) to read as follows:
       (a)  A person who is engaged in the wholesale distribution of
a prescription drug, including a repackager but excluding the
original manufacturer [and the original labeler of a prescription
drug], shall provide a pedigree for each prescription drug that
leaves or at any time has left [is not distributed through] the
normal distribution channel [chain] and is sold, traded, or
transferred to any other person.
       (b-1)  A retail pharmacy or pharmacy warehouse is required to
comply with this section only if the pharmacy or warehouse engages
in the wholesale distribution of a prescription drug.
       (d)  A person who is engaged in the wholesale distribution of
a prescription drug, including a repackager, but excluding the
original manufacturer of the finished form of a prescription drug, 
and who is in possession of a pedigree for a prescription drug must
verify before distributing the prescription drug that each
transaction listed on the pedigree has occurred.
       SECTION 11.  Section 431.413, Health and Safety Code, is
amended by amending Subsections (a), (c), and (e) and adding
Subsection (e-1) to read as follows:
       (a)  A pedigree must include all necessary identifying
information concerning each sale in the product's chain of
distribution from the manufacturer, or from the manufacturer's
third-party logistics provider, co-licensed product partner, or
exclusive distributor, through acquisition and sale by a wholesale
distributor or repackager, until final sale to a pharmacy or other
person dispensing or administering the drug. At a minimum, the
chain of distribution information must include:
             (1)  the name, address, telephone number, and, if
available, the e-mail address of each person who owns [or
possesses] the prescription drug and each wholesale distributor of
the prescription drug[, except common carriers and logistics
providers];
             (2)  [the signature of each owner of the prescription
drug;
             [(3)]  the name and address of each location from which
the product was shipped, if different from the owner's name and
address;
             (3) [(4)]  the transaction dates; and
             (4) [(5)]  certification that each recipient has
authenticated the pedigree.
       (c)  Each pedigree statement must be:
             (1)  maintained by the purchaser and the wholesale
distributor for at least three years; and
             (2)  available for inspection and photocopying not
later than the fifth business day after the date [on] a request is
submitted by the department or a peace officer in this state.
       (e)  The department shall:
             (1)  conduct a study on the implementation of
electronic pedigrees; and
             (2)  in conducting the study under Subdivision (1),
consult with manufacturers, distributors, and pharmacies
responsible for the sale and distribution of prescription drugs in
this state[; and
             [(3)  based on the results of the study, establish an
implementation date, which may not be earlier than December 31,
2007, for electronic pedigrees].
       (e-1)  If, after consulting with manufacturers,
distributors, and pharmacies responsible for the sale and
distribution of prescription drugs in this state, the department
determines that electronic track and trace pedigree technology is
universally available across the entire prescription
pharmaceutical supply chain, the department shall establish a
targeted implementation date for electronic track and trace
pedigree technology. After the department has established a
targeted implementation date, the department may revise the date.
The targeted implementation date may not be earlier than July 1,
2010.
       SECTION 12.  Section 431.414, Health and Safety Code, is
amended by adding Subsection (a-1) to read as follows:
       (a-1)  The commissioner of state health services may suspend
or revoke a license if the license holder no longer meets the
qualifications for obtaining a license under Section 431.405.
       SECTION 13.  Section 431.415, Health and Safety Code, is
amended by amending Subsection (a) and adding Subsection (a-1) to
read as follows:
       (a)  Except as provided by Subsection (a-1), the [The]
commissioner of state health services shall issue an order
requiring a person, including a [manufacturer,] distributor[,] or
retailer of a prescription drug, to immediately cease distribution
of the drug if the commissioner determines there is a reasonable
probability that:
             (1)  a wholesale distributor has:
                   (A)  violated this subchapter;
                   (B)  falsified a pedigree; or
                   (C)  sold, distributed, transferred,
manufactured, repackaged, handled, or held a counterfeit
prescription drug intended for human use that could cause serious
adverse health consequences or death; and
             (2)  other procedures would result in unreasonable
delay.
       (a-1)  This section does not authorize the commissioner of
state health services to issue a cease and desist order against a
manufacturer.
       SECTION 14.  Subchapter N, Chapter 431, Health and Safety
Code, is amended by adding Sections 431.416 and 431.417 to read as
follows:
       Sec. 431.416.  PROHIBITED ACTS. (a)  The following acts and
the causing of or aiding or abetting of the following acts within
this state are unlawful and prohibited:
             (1)  the failure to obtain a license in accordance with
this subchapter;
             (2)  operating without a valid license when a license
is required by this subchapter;
             (3)  the purchase or receipt of a prescription drug
from a pharmacy in violation of Section 431.411(a) or (a-1);
             (4)  if a license is required under Section 431.411(b),
the sale, distribution, or transfer of a prescription drug to a
person who is not authorized under the laws of the jurisdiction in
which the person receives the prescription drug to receive the
prescription drug;
             (5)  the failure to deliver a prescription drug to a
specified premise, as required by Section 431.411(c);
             (6)  accepting payment or credit for the sale of a
prescription drug in violation of Section 431.411(e);
             (7)  the failure to maintain or provide a pedigree as
required by this subchapter;
             (8)  the failure to obtain, pass, or authenticate a
pedigree as required by this subchapter;
             (9)  providing this state or a representative of this
state or a federal official with a false or fraudulent record
regarding any matter covered under this subchapter;
             (10)  making a false or fraudulent statement regarding
any matter covered under this subchapter;
             (11)  obtaining or attempting to obtain a prescription
drug by fraud, deceit, or misrepresentation;
             (12)  engaging in misrepresentation or fraud in the
distribution of a prescription drug;
             (13)  except for a manufacturer's wholesale
distribution of a prescription drug that has been delivered into
commerce pursuant to an application approved under federal law by
the United States Food and Drug Administration, the manufacture,
repacking, sale, transfer, delivery, or holding of, or offering for
sale, any prescription drug that is adulterated, misbranded,
counterfeit, or suspected of being counterfeit or has otherwise
been rendered unfit for distribution;
             (14)  except for a manufacturer's wholesale
distribution of a prescription drug that has been delivered into
commerce pursuant to an application approved under federal law by
the United States Food and Drug Administration, the adulteration,
misbranding, or counterfeiting of any prescription drug;
             (15)  the receipt of a prescription drug that is
adulterated, misbranded, stolen, obtained by fraud or deceit,
counterfeit, or suspected of being counterfeit, and the delivery or
proffered delivery of such a drug for payment or otherwise; and
             (16)  the alteration, mutilation, destruction,
obliteration, or removal of all or any part of the labeling of a
prescription drug or the commission of any other act with respect to
a prescription drug that results in the prescription drug being
misbranded.
       (b)  Subsection (a) does not apply to a prescription drug
manufacturer, or an agent of a prescription drug manufacturer, who
is obtaining or attempting to obtain a prescription drug for the
sole purpose of testing the prescription drug for authenticity.
       Sec. 431.417.  CRIMINAL PENALTIES. (a)  A person commits an
offense if the person knowingly or with criminal negligence engages
in the wholesale distribution of prescription drugs in violation of
this subchapter.
       (b)  Except as otherwise provided by this section, an offense
under this section is a felony punishable by imprisonment for a term
not to exceed 15 years, a fine not to exceed $50,000, or both
imprisonment and a fine.
       (c)  If it is shown on the trial of an offense under this
section that the person knowingly engaged in the wholesale
distribution of prescription drugs in violation of this subchapter,
the offense is a felony punishable by imprisonment for a term of not
more than 99 years or less than 15 years, a fine not to exceed
$500,000, or both imprisonment and a fine.
       (d)  If conduct constituting an offense under this  section
also constitutes an offense under any other law, the actor may be
prosecuted under this section, the other law, or both.
       SECTION 15.  Subsections (a-1) and (a-2), Section 431.059,
and Subsections (b) and (c), Section 431.412, Health and Safety
Code, are repealed.
       SECTION 16.  The executive commissioner of the Health and
Human Services Commission shall adopt the rules necessary to
implement the changes in law made by this Act not later than
December 1, 2007.
       SECTION 17.  The change in law made by this Act applies only
to an offense committed on or after the effective date of this Act.
An offense committed before the effective date of this Act is
covered by the law in effect when the offense was committed, and the
former law is continued in effect for that purpose. For purposes of
this section, an offense was committed before the effective date of
this Act if any element of the offense was committed before that
date.
       SECTION 18.  This Act takes effect September 1, 2007.